- CDC’s advisory committee on Friday formally recommended booster shots for Pfizer-BioNtech and Moderna’s COVID-19 vaccine.
- Members voted 11-0 to suggest that adults aged 18 to 49 could get a ‘booster’ and that those 50 and older should get a ‘booster’.
- It Comes on the Same Day the FDA Authorized Booster Shots for Over 18s
- The new recommendation means all adults are now eligible to receive a booster made by any of the three vaccines approved in the US
- Pfizer’s booster shot is the third dose of the two-shot vaccine and half the dose of Moderna
- As of Friday, 32.4 million Americans had a seven-day rolling average of 700,000 . got booster shot with more than
The Centers for Disease Control and Prevention (CDC) advisory committee on Friday unanimously recommended booster shots of Pfizer-BioNtech and Moderna’s COVID-19 vaccine for all adults.
It comes on the same day that the US Food and Drug Administration (FDA) authorized the shots.
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 11-0 that people ages 18 to 49 can get a booster while those 50 and older should get a booster.
Prior to the authorization, the companies’ booster shots were only authorized for people age 65 and older or those at high risk because of underlying conditions or their jobs.
But now — the Johnson & Johnson booster is already approved for Americans age 18 and older — it means that fully vaccinated people in the US can get any one of three booster shots.
The move complements the Biden administration’s goal, announced over the summer, to provide an additional dose to every adult.
The final step before booster shots are widely administered to the general public is a nod by CDC Director Dr. Rochelle Valensky.
FDA authorizes booster shots for Pfizer-BioEntech and Moderna’s COVID-19 vaccine Friday: Pfizer-BioEntech and Moderna vaccination vials, July 2021
In August, boosters were approved for immunocompromised Americans who received the Pfizer or Moderna vaccine after data showed they were less likely to develop high antibody levels after two doses.
Shortly after, the White House announced that booster shots would be available to all Americans starting September 20 because of data suggesting the effectiveness of early shots was low.
At the time, Moderna said the data citing the declining effectiveness of the shots in preventing infection and the increased antibody levels provided by the third shots, for people age 18 and older after receiving the second shot. Supports use.
But many scientists, including senior FDA officials, disagreed and argued that vaccines are still highly effective in preventing serious illness and death.
Pfizer’s booster is the third dose of the two-shot vaccine.
The team also released data from a clinical trial involving 23 Participants who took part in Pfizer’s early-stage trials last year.
Each had received two doses of the vaccine and was given a booster dose at least six months later.
11 of the participants were in Young adult groups aged 18 to 55 and 12 were aged 65 to 85.
After the third dose, neutralizing antibodies against the original strain of the virus increased five-fold in the 18 to 55 age group and seven-fold in the 65 to 85 age group.
As of Friday, 32.4 million Americans had a seven-day rolling average of 700,000 . got booster shot with more than
Pfizer said the data shows the efficacy of two doses decreases from 96.2% to 83.7% after six months, but the third dose increases antibody levels (above)
In August, the company said its preliminary data showed people who received a booster dose between six and 12 months after their last dose had a higher level of protection.
document Published in September it suggests that protection from two doses of the Pfizer vaccine drops from 96.2 percent at seven days after dose 2 to 90.1 percent after two months to 83.7 percent after six months.
What’s more, Pfizer cited data from Israel showing that people who were fully vaccinated in January 2021 had a 2.26-fold increased risk for breakthrough infection compared to those who were fully vaccinated in April 2021.
Meanwhile, Moderna’s booster is a 50 microgram (μg) dose — half the dose of its original vaccine.
data in May has shown booster increased levels of neutralizing antibodies against the original virus and variants, including beta and gamma variants.
The company then released data in September showing that people who received its COVID-19 vaccine last year were almost twice as likely to have a successful infection than those who were recently vaccinated.
There were 88 successful cases of COVID-19 among vaccinated Americans from December 2020 to March 2021.
By comparison, there were 162 cases – 1.8 times more – among those vaccinated between July 2020 and December 2020.
The Cambridge, Massachusetts-based company said the data provided evidence for giving booster doses to fully vaccinated people.
“This emergency use authorization comes at a critical time as we enter the winter months and face rising COVID-19 cases and hospitalizations across the country,” Moderna CEO Stephen Bansell said in a statement. ”
‘We thank the FDA for their review, and believe in the strong clinical evidence that a 50 microgram booster dose of mRNA-1273 induces a robust immune response against COVID-19.’
Dr Anthony Fauci said on Tuesday that the US is seeing a ‘surge’ in COVID-19 hospitalizations among fully vaccinated people who do not have a booster. Image: Fauci speaks at the hearing of the Senate Health, Education, Labor and Pensions Committee, November 2021
As of Friday, 32.4 million Americans have received a booster shot.
It comes as Dr Anthony Fauci said that COVID-19 hospitalizations are on the rise among fully vaccinated people who have not had a booster shot.
‘What we’re starting to see now is hospitalizations among people who have been vaccinated, but…